Key facts
- Orikine Bio’s last known valuation is $17.7M (Jul 2023).
- It has raised $6.8M; the latest was Early Stage VC in Jan 2026.
- Notable investors include INNVIERTE SICC, Asabys Partners, AdBio partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Orikine Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Orikine Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orikine Bio
Developer of cytokine-based therapies designed for the treatment of autoimmune and inflammatory diseases. The company engages in advancing the field of engineered cytokines with biological features for the treatment of immune-mediated diseases, enabling clients to avuil therapies that have the power to reshape the lives of patients around the globe.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2022
- Employees
- 10
- Website
- orikine.bio/
- Ownership
- Privately Held (backing)
Orikine Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orikine Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orikine Bio in its N-PORT filings yet. We sweep new filings monthly.